Cyclopharm Limited (ASX: CYC), a radiopharmaceutical company focused on improving patient care outcomes through nuclear medicine, has announced that its Technegas product has been approved for clinical use at the National Institutes of Health (NIH) in Bethesda, Maryland, USA. A formal purchase order has been received, with installation expected in the coming weeks. Cyclopharm achieves its objective primarily through the provision of its core radiopharmaceutical product, Technegas, used in functional lung ventilation imaging.
The NIH Clinical Centre, recognised globally for advancing medical standards, will utilise Technegas for clinical ventilation imaging within its protocol-driven clinical program. This approval marks a significant clinical and strategic milestone for Cyclopharm’s US expansion, leveraging the company’s existing five-year Federal Supply Schedule agreement. This agreement streamlines procurement access across US federal healthcare institutions, supporting the increasing adoption of Technegas at US Department of Veterans Affairs (VA) hospitals and military treatment facilities.
Beyond its application in pulmonary embolism diagnosis, Technegas is expected to expand its utility into other pulmonary diseases. NIH’s leadership in translational research provides a visible platform to explore Technegas in conditions such as chronic obstructive pulmonary disease (COPD), asthma, and oncology-related pulmonary complications. The unique characteristics of Technegas deliver true functional ventilation imaging with high peripheral deposition, supporting more precise assessment of pulmonary physiology at significantly lower radiation doses compared to CTPA imaging.
According to Cyclopharm, this approval provides institutional validation and supports expansion beyond pulmonary embolism, driving increased system utilisation and recurring revenue. NIH-led research often influences multicentre collaboration and clinical guidelines, creating further adoption opportunities. The installation strengthens Cyclopharm’s US credibility as the company establishes reference centres and expands long-term institutional penetration.
